GlassScriptPhysician profile
Robert W Hindman
NPI 1992705552
$6,638.64
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $1,561 · 2021: $2,951 · 2022: $276 · 2024: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $103.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,481.53 | 2019-2022 | |
| Glaxosmithkline, LLC. | $781.06 | 2019-2024 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $672.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $580.23 | 2019-2022 | |
| Insmed, INC. | $322.57 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $294.70 | 2019-2021 | |
| Harmony Biosciences LLC | $278.67 | 2021-2022 | |
| Mylan Specialty L.P. | $270.35 | 2019-2022 | |
| Advanced Respiratory, INC | $264.86 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.04 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $200.00 | 2019-2021 | |
| Grifols USA, LLC | $183.97 | 2019-2021 | |
| Genentech USA, INC. | $156.38 | 2019-2021 | |
| United Therapeutics Corporation | $154.58 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $105.26 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $93.61 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $86.82 | 2019 | |
| Genzyme Corporation | $81.65 | 2019-2021 | |
| Shire North American Group INC | $61.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $49.87 | 2019-2020 | |
| Circassia INC. | $47.62 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $36.67 | 2019-2021 | |
| Csl Behring | $32.27 | 2019 | |
| Biomerieux INC | $30.01 | 2020 | |
| Mallinckrodt Enterprises LLC | $28.47 | 2019 | |
| Mallinckrodt Hospital Products INC. | $27.23 | 2020 | |
| Paratek Pharmaceuticals, INC. | $19.79 | 2021 | |
| Pfizer INC. | $19.45 | 2021 | |
| Resmed Corp | $17.54 | 2021 | |
| Nabriva Therapeutics, Plc | $17.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.87 | 2019 | |
| Eisai INC. | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hindman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.